Skip to main content
Top
Published in: Endocrine Pathology 3/2018

01-09-2018

A Case of Gastric Neuroendocrine Neoplasm with Mixed Grade: a Distinct Type of “High”-grade Well-Differentiated Neuroendocrine Neoplasm

Authors: Elia Guadagno, Gaetano Luglio, Alessandro Iacobelli, Giorgio Borrelli, Antonio Castaldi, Gaetano De Rosa, Marialaura Del Basso De Caro

Published in: Endocrine Pathology | Issue 3/2018

Login to get access

Abstract

Grade 3 neuroendocrine tumor (NET G3) is a rare new entity that has recently been introduced in the classification of neuroendocrine neoplasms of the pancreas. It is a well-differentiated form, with a high proliferative activity (Ki67 > 20%), and it represents a category whose prognosis is intermediate between NET G2 and poorly differentiated neuroendocrine carcinoma (NEC G3). In sites other than the pancreas, this new category is by far less coded. Herein is reported a case of NET G3 of the stomach, the 13th described in literature. The patient was a 71-year-old man with a mass in the gastric fundus. Histological examination revealed a neuroendocrine tumor that was mostly composed by areas with conventional well-differentiated features and intermediate proliferative rate (< 20 mitoses/10 HPFs and 7% Ki67); part of the tumor was characterized by increased nuclear atypia, a confluent growth pattern, intermediate mitotic activity, and high Ki67 value (25%). The tumor was studied immunohistochemically and molecularly, and the only alteration that came out was MEN1 gene mutation (Lau584SerfsTer5) in both the high- and low-grade components. According to the actual classification of gastric neuroendocrine neoplasms, this case is labeled as NEC G3 but it should be named NET G3, with a much better prognosis than the former. Overall, both morphological pattern and the Ki67 value should be mentioned in the histological report in cases of high-grade neuroendocrine neoplasms because of its clinical significance in defining the prognosis and for new potential therapeutic approaches.
Literature
2.
go back to reference Rindi G, Arnold R, Bosman FT. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, et al., editors. WHO classification of tumors of the digestive system. Lyon: IARC; 2010. Rindi G, Arnold R, Bosman FT. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, et al., editors. WHO classification of tumors of the digestive system. Lyon: IARC; 2010.
3.
go back to reference Grillo F, Albertelli M, Annunziata F, Boschetti M, Caff A, Pigozzi S, Ferone D, Mastracci L. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? Endocrine. 53; 58–62, 2016CrossRefPubMed Grillo F, Albertelli M, Annunziata F, Boschetti M, Caff A, Pigozzi S, Ferone D, Mastracci L. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? Endocrine. 53; 58–62, 2016CrossRefPubMed
4.
go back to reference Öberg K, Knigge U, Kwekkeboom D ESMO Guidelines Working Group et al., Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol; 23 Suppl 7, vii124–vii130, 2012PubMed Öberg K, Knigge U, Kwekkeboom D ESMO Guidelines Working Group et al., Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol; 23 Suppl 7, vii124–vii130, 2012PubMed
5.
go back to reference Remo A, Fassan M, Lanza G et al. Immunohistochemical evaluation of mismatch repair proteins in colorectal carcinoma: the AIFEG/GIPAD proposal. PATHOLOGICA. 107:104–109, 2015 Remo A, Fassan M, Lanza G et al. Immunohistochemical evaluation of mismatch repair proteins in colorectal carcinoma: the AIFEG/GIPAD proposal. PATHOLOGICA. 107:104–109, 2015
6.
go back to reference Klöppel G, Couvelard A, Hruban RH, Klimstra DS, Komminoth P, Osamura RY, Perren A, Rindi G. WHO classification of neoplasms of the neuroendocrine pancreas. In: WHO classification of tumors of endocrine organs. Eds Lloyd RV, Osamura RY, Klöppel G, Rosai J. Lyon, IARC 2017 Klöppel G, Couvelard A, Hruban RH, Klimstra DS, Komminoth P, Osamura RY, Perren A, Rindi G. WHO classification of neoplasms of the neuroendocrine pancreas. In: WHO classification of tumors of endocrine organs. Eds Lloyd RV, Osamura RY, Klöppel G, Rosai J. Lyon, IARC 2017
7.
go back to reference Heetfeld M, Chougnet CN, Olsen IH et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. EndocrRelatCancer. 22: 657–664, 2015 Heetfeld M, Chougnet CN, Olsen IH et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. EndocrRelatCancer. 22: 657–664, 2015
8.
go back to reference Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, Pisa E, Barberis M, Vanoli A, Buzzoni R, Pusceddu S, Concas L, Sessa F, Solcia E, Capella C, Fazio N, la Rosa S The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories.Neuroendocrinology.104: 85–93, 2017;CrossRefPubMed Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, Pisa E, Barberis M, Vanoli A, Buzzoni R, Pusceddu S, Concas L, Sessa F, Solcia E, Capella C, Fazio N, la Rosa S The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories.Neuroendocrinology.104: 85–93, 2017;CrossRefPubMed
9.
go back to reference Lee HE, Mounajjed T, Erickson LA et al. Sporadic gastric well-differentiated neuroendocrine tumors have a higher Ki-67 proliferative index. Endocr Pathol. 27: 259–267, 2016CrossRefPubMed Lee HE, Mounajjed T, Erickson LA et al. Sporadic gastric well-differentiated neuroendocrine tumors have a higher Ki-67 proliferative index. Endocr Pathol. 27: 259–267, 2016CrossRefPubMed
10.
go back to reference Furlan D, Cerutti R, Uccella S, la Rosa S, Rigoli E, Genasetti A, Capella C Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin Cancer Res. 10:947–957, 2004CrossRefPubMed Furlan D, Cerutti R, Uccella S, la Rosa S, Rigoli E, Genasetti A, Capella C Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin Cancer Res. 10:947–957, 2004CrossRefPubMed
11.
go back to reference Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, DeMarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue CA Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J SurgPathol. 36: 173–184, 2012CrossRef Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, DeMarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue CA Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J SurgPathol. 36: 173–184, 2012CrossRef
12.
go back to reference Vélayoudom-Céphise FL, Duvillard P, Foucan L et al. Are G3 ENETS neuroendocrine neoplasmsheterogeneous? Endocr Relat Cancer. 20:649–657, 2013CrossRefPubMed Vélayoudom-Céphise FL, Duvillard P, Foucan L et al. Are G3 ENETS neuroendocrine neoplasmsheterogeneous? Endocr Relat Cancer. 20:649–657, 2013CrossRefPubMed
13.
go back to reference Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J SurgPathol. 39: 683–690, 2015CrossRef Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J SurgPathol. 39: 683–690, 2015CrossRef
14.
go back to reference Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 24: 152–160, 2013CrossRefPubMed Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 24: 152–160, 2013CrossRefPubMed
15.
go back to reference Sorbye H, Strosberg J, Baudin et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 120: 2814–2823, 2014CrossRefPubMed Sorbye H, Strosberg J, Baudin et al. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 120: 2814–2823, 2014CrossRefPubMed
16.
go back to reference Tang LH, Untch BR, Reidy DL et al. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 22: 4273, 2016CrossRef Tang LH, Untch BR, Reidy DL et al. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 22: 4273, 2016CrossRef
17.
go back to reference Wallace WA. The challenge of classifying poorly differentiated tumours in the lung. Histopathology. 54:28–42, 2009CrossRefPubMed Wallace WA. The challenge of classifying poorly differentiated tumours in the lung. Histopathology. 54:28–42, 2009CrossRefPubMed
18.
go back to reference Fazio N & Milione M. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Cancer Treat Rev; 50:61–67, 2016CrossRefPubMed Fazio N & Milione M. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Cancer Treat Rev; 50:61–67, 2016CrossRefPubMed
Metadata
Title
A Case of Gastric Neuroendocrine Neoplasm with Mixed Grade: a Distinct Type of “High”-grade Well-Differentiated Neuroendocrine Neoplasm
Authors
Elia Guadagno
Gaetano Luglio
Alessandro Iacobelli
Giorgio Borrelli
Antonio Castaldi
Gaetano De Rosa
Marialaura Del Basso De Caro
Publication date
01-09-2018
Publisher
Springer US
Published in
Endocrine Pathology / Issue 3/2018
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-018-9528-5

Other articles of this Issue 3/2018

Endocrine Pathology 3/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.